Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat

Peptides

Volumn 31, Issue 4, 2010, Pages 630-638

  Pang, Jinjiang ^a   Xu, Qihua ^a   Xu, Xiangbin ^a   Yin, Hongchao ^a   Xu, Rongkun ^a   Guo, Shu ^a   Hao, Wei ^a   Wang, Luya ^b   Chen, Chen ^c   Cao, Ji Min ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Atherosclerosis; Calcification; Foam cell; Growth hormone secretagogues; Nitric oxide

Indexed keywords

ANGIOTENSIN II; CALCIUM; CD36 ANTIGEN; COLECALCIFEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXARELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PROPYLTHIOURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALCIUM BLOOD LEVEL; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; EMULSION; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID DIET; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; ATHEROSCLEROSIS; CHOLECALCIFEROL; DIETARY FATS; FEMALE; GHRELIN; HUMANS; LIPOPROTEINS; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OLIGOPEPTIDES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 77949270217     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.11.007     Document Type: Article

References (57)

1. Aji W., Ravalli S., Szabolcs M., Jiang X.C., Sciacca R.R., Michler R.E., et al. l-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95 (1997) 430-437
2. Avallone R., Demers A., Rodrigue-Way A., Bujold K., Harb D., Anghel S., et al. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway. Mol Endocrinol 20 (2006) 3165-3178
3. Baldanzi G., Filigheddu N., Cutrupi S., Catapano F., Bonissoni S., Fubini A., et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159 (2002) 1029-1037
4. Bath P.M., Hassall D.G., Gladwin A.M., Palmer R.M., and Martin J.F. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arteriosc Thromb 11 (1991) 254-260
5. Bodart V., Bouchard J.F., McNicoll N., Escher E., Carriere P., Ghigo E., et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 85 (1999) 796-802
6. Bodart V., Febbraio M., Demers A., McNicoll N., Pohankova P., Perreault A., et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 90 (2002) 844-849
7. Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol 88 (2001) 20E-22E
8. Cao J.M., Ong H., and Chen C. Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol Metab 17 (2006) 13-18
9. Cardús A., Parisi E., Gallego C., Aldea M., Fernández E., and Valdivielso J.M. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69 (2006) 1377-1384
10. Castellot Jr. J.J., Favreau L.V., Karnovsky M.J., and Rosenberg R.D. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem 257 (1982) 11256-11260
11. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.A., and Billingham M.E. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J Clin Invest 90 (1992) 1168-1172
12. Cornwell T.L., Arnold E., Boerth N.J., and Lincoln T.M. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 267 (1994) C1405-C1413
13. Daviet L., and McGregor J.L. Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb Haemost 78 (1997) 65-69
14. de Graaf J.C., Banga J.D., Moncada S., Palmer R.M., de Groot P.G., and Sixma J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85 (1992) 2284-2290
15. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
16. Dubey R.K., Jackson E.K., and Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 96 (1995) 141-149
17. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275 (1997) 661-665
18. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268 (1993) 11811-11816
19. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105 (2000) 1049-1056
20. Feng J., Han J., Pearce S.F., Silverstein R.L., Gotto Jr. A.M., Hajjar D.P., et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 41 (2000) 688-696
21. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
22. Gallis B., Corthals G.L., Goodlett D.R., Ueba H., Kim F., Presnell S.R., et al. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J Biol Chem 274 (1999) 30101-30108
23. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
24. Gauthier T.W., Scalia R., Murohara T., Guo J.P., and Lefer A.M. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 15 (1995) 1652-1659
25. Han J., Hajjar D.P., Febbraio M., and Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 272 (1997) 21654-21659
26. Hsu J.J., Tintut Y., and Demer L.L. Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol 3 (2008) 1542-1547
27. Hung C.R., Chen W.H., and Wang P.S. Protective effect of lysozyme chloride on gastric oxidative stress and hemorrhagic ulcers in severe atherosclerotic rats. Med Sci Monit 13 (2007) BR271-BR279
28. Iantorno M., Chen H., Kim J.A., Tesauro M., Lauro D., Cardillo C., et al. Ghrelin has novel vascular actions that mimic PI3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292 (2007) E756-E764
29. Ishibashi S., Herz J., Maeda N., Goldstein J.L., and Brown M.S. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 91 (1994) 4431-4435
30. Itoh H., Pratt R.E., and Dzau V.J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86 (1990) 1690-1697
31. Kozaki K., Akishita M., Eto M., Yoshizumi M., Toba K., Inoue S., et al. Role of activin-A and follistatin in foam cell formation of THP-1 macrophages. Arterioscler Thromb Vasc Biol 17 (1997) 2389-2394
32. Li W.G., Gavrila D., Liu X., Wang L., Gunnlaugsson S., Stoll L.L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109 (2004) 2221-2226
33. Locatelli V., Rossoni G., Schweiger F., Torsello A., De Gennaro Colonna V., et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140 (1999) 4024-4031
34. Marleau S., Harb D., Bujold K., Avallone R., Iken K., Wang Y., et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 19 (2005) 1869-1871
35. Moore K.J., Kunjathoor V.V., Koehn S.L., Manning J.J., Tseng A.A., Silver J.M., et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 115 (2005) 2192-2201
36. Muccioli G., Broglio F., Valetto M.R., Ghe C., Catapano F., Graziani A., et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 61 (2000) 27-31
37. Nagaya N., Kojima M., Uematsu M., Yamagishi M., Hosoda H., Oya H., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280 (2001) R1483-R1487
38. Nakata A., Nakagawa Y., Nishida M., Nozaki S., Miyagawa J., Nakagawa T., et al. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19 (1999) 1333-1339
39. Naruse K., Shimizu K., Muramatsu M., Toki Y., Miyazaki Y., Okumura K., et al. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 14 (1994) 746-752
40. Nava E., Noll G., and Luscher T.F. Nitric oxide in cardiovascular diseases. Ann Med 27 (1995) 343-351
41. Niebauer J., Schwarzacher S.P., Hayase M., Wang B., Kernoff R.S., Cooke J.P., et al. Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis. Circulation 100 (1999) 1830-1835
42. Nozaki S., Kashiwagi H., Yamashita S., Nakagawa T., Kostner B., Tomiyama Y., et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96 (1995) 1859-1865
43. Pang J.J., Xu R.K., Xu X.B., Cao J.M., Ni C., Zhu W.L., et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am J Physiol Heart Circ Physiol 286 (2004) H1063-H1069
44. Proudfoot D., Davies J.D., Skepper J.N., Weissberg P.L., and Shanahan C.M. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 106 (2002) 3044-3050
45. Rossi F., Bertone C., Petricca S., and Santiemma V. Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. Atherosclerosis 192 (2007) 291-297
46. Rossi F., Castelli A., Bianco M.J., Bertone C., Brama M., and Santiemma V. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis 203 (2009) 97-104
47. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
48. Schwartz C.J., Valente A.J., and Sprague E.A. A modern view of atherogenesis. Am J Cardiol 71 (1993) 9B-14B
49. Shimizu Y., Nagaya N., Teranishi Y., Imazu M., Yamamoto H., Shokawa T., et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 310 (2003) 830-835
50. Sukovich D.A., Kauser K., Shirley F.D., DelVecchio V., Halks-Miller M., and Rubanyi G.M. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler Thromb Vasc Biol 18 (1998) 1498-1505
51. Tang F.T., Chen S.R., Wu X.Q., Wang T.Q., Chen J.W., Li J., et al. Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int 79 (2006) 326-339
52. Thomas K.R., and Capecchi M.R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51 (1987) 503-512
53. van Berkel T.J., Out R., Hoekstra M., Kuiper J., Biessen E., and van Eck M. Scavenger receptors: friend or foe in atherosclerosis?. Curr Opin Lipidol 16 (2005) 525-535
54. Wallin R., Wajih N., Greenwood G.T., and Sane D.C. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 21 (2001) 274-301
55. Wang B.Y., Ho H.K., Lin P.S., Schwarzacher S.P., Pollman M.J., Gibbons G.H., et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 99 (1999) 1236-1241
56. Wu Y., Li J., Wang J., Si Q., Zhang J., Jiang Y., et al. Anti-atherogenic effects of centipede acidic protein in rats fed an atherogenic diet. J Ethnopharmacol 122 (2009) 509-516
57. Xu X.B., Pang J.J., Cao J.M., Ni C., Xu R.K., Peng X.Z., et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 289 (2005) H1643-H1651